No Data
No Data
Shanghai Henlius Biotech Gets the Nod From Japan's PMDA for Japan Trials
Shanghai Henlius Biotech (HKG:2696) said Japan's Pharmaceuticals and Medical Devices Agency (PMDA) gave an implied approval to the serplulimab injection in combination with bevacizumab injection and c
Henlius Biotech Launches Phase 3 Cancer Trial in Japan
Henlius (02696.HK): Hansuo (Sulilumab Injection) combined with Bevacizumab Injection combined with chemotherapy has been granted permission to conduct a Phase III clinical trial for first-line treatment of metastatic colorectal cancer in Japan at multiple
Henlius (02696.HK) announced on July 2nd that the international multicenter Phase 3 clinical trial notification for HanSi Zhuang (Sulilumab injection) in combination with Bevacizumab monoclonal antibody injection and chemotherapy for first-line treatment of metastatic colorectal cancer (mCRC) submitted to the Japan Pharmaceuticals and Medical Devices Agency (PMDA) has received tacit approval. According to relevant regulations, the relevant clinical trials can be conducted in Japan. HanSi Zhuang is an innovative anti-PD-1 monoclonal antibody independently developed by the company, and was approved for marketing in China (excluding Hong Kong, Macau, and Taiwan) in March 2022. As of the announcement.
Express News | Shanghai Henlius Biotech - Relevant Clinical Trial for First-Line Treatment of Metastatic Colorectal Cancer in Japan
Express News | Shanghai Henlius Biotech - Hansizhuang (Serplulimab Injection) With Bevacizumab Injection & Chemotherapy Permitted for Phase 3 Clinical Trial
Henlius (02696.HK): Appointing Mao Yingbo as Deputy General Manager and Chief Financial Officer of the company.
On July 1st, Gelonhui announced that, based on the nomination of the company's CEO, Zhu Jun, Mao Yingbo was appointed as the Vice President and Chief Financial Officer of the company, reporting to CEO Zhu Jun, starting from July 1st, 2024. Zhu Jun will no longer serve as the Chief Financial Officer, but will continue to serve as the company's Executive Director and CEO.
No Data